Literature DB >> 25305510

Preventive prospective of triclosan and triclosan-liposomal nanoparticles against experimental infection with a cystogenic ME49 strain of Toxoplasma gondii.

Lobna A El-Zawawy1, Doaa El-Said1, Shereen F Mossallam2, Heba S Ramadan3, Salwa S Younis1.   

Abstract

The preventative effect of triclosan (TS) and TS liposomal nanoparticles was studied on the early establishment of chronic infection with Toxoplasma gondii (T. gondii). Swiss albino mice were orally infected with 10 cysts of avirulent ME49 strain of T. gondii, and 2 weeks later they were orally treated with dual daily doses of 200mg/kg and 120 mg/kg TS and TS liposomes for 30 days; respectively. Effect of TS and TS liposomes was parasitologically and ultrastructurally evaluated, versus infected non-treated control. Their safety was biochemically assessed. Parasitologically, both TS and TS liposomes induced significant reduction in mice mortality, brain parasite burden and infectivity of cysts obtained from the brains of treated mice. Ultrastructurally, scanning electron microscopy of cysts obtained from infected mice treated with either TS or TS liposomes showed surface irregularities, protrusions and depressions. Transmission electron microscopy revealed disintegration of the cyst wall and vacuolation of the bradyzoites with disintegration of plasma membranes of both cysts and bradyzoites whether treated with TS or TS liposomes. Biochemical study reflected the safety of the TS and TS liposomes. Therefore, TS proved an effective, promising and safe preventive drug against early establishment of chronic toxoplasmosis. Loading TS on liposomes marginally enhanced its efficacy against T. gondii cysts yet allowed its use in a lower dose.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cysts; Liposomes; ME49 avirulent strain; Toxoplasma gondii; Triclosan

Mesh:

Substances:

Year:  2014        PMID: 25305510     DOI: 10.1016/j.actatropica.2014.09.020

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  8 in total

Review 1.  Nanomedicine advances in toxoplasmosis: diagnostic, treatment, and vaccine applications.

Authors:  João Paulo Assolini; Virginia Márcia Concato; Manoela Daiele Gonçalves; Amanda Cristina Machado Carloto; Ivete Conchon-Costa; Wander Rogério Pavanelli; Francine Nesello Melanda; Idessania Nazareth Costa
Journal:  Parasitol Res       Date:  2017-05-05       Impact factor: 2.289

Review 2.  Clinically Available Medicines Demonstrating Anti-Toxoplasma Activity.

Authors:  Andrew J Neville; Sydney J Zach; Xiaofang Wang; Joshua J Larson; Abigail K Judge; Lisa A Davis; Jonathan L Vennerstrom; Paul H Davis
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

3.  Repurposing auranofin for treatment of Experimental Cerebral Toxoplasmosis.

Authors:  Iman Fathy Abou-El-Naga; Nermine Mogahed Fawzy Hussein Mogahed
Journal:  Acta Parasitol       Date:  2021-02-08       Impact factor: 1.440

Review 4.  Activities of anti-Toxoplasma drugs and compounds against tissue cysts in the last three decades (1987 to 2017), a systematic review.

Authors:  Mahbobeh Montazeri; Saeed Mehrzadi; Mehdi Sharif; Shahabeddin Sarvi; Shayesteh Shahdin; Ahmad Daryani
Journal:  Parasitol Res       Date:  2018-08-08       Impact factor: 2.289

5.  Effect of HIV aspartyl protease inhibitors on experimental infection with a cystogenic Me49 strain of Toxoplasma gondii.

Authors:  Iman Fathy Abou-El-Naga; Maha Mohamed Gomaa; Samar Nabil ElAchy
Journal:  Pathog Glob Health       Date:  2021-08-22       Impact factor: 3.735

Review 6.  A Systematic Review of In vitro and In vivo Activities of Anti-Toxoplasma Drugs and Compounds (2006-2016).

Authors:  Mahbobeh Montazeri; Mehdi Sharif; Shahabeddin Sarvi; Saeed Mehrzadi; Ehsan Ahmadpour; Ahmad Daryani
Journal:  Front Microbiol       Date:  2017-01-20       Impact factor: 5.640

7.  Rosuvastatin revert memory impairment and anxiogenic-like effect in mice infected with the chronic ME-49 strain of Toxoplasma gondii.

Authors:  Fernanda Ferreira Evangelista; Willian Costa-Ferreira; Francini Martini Mantelo; Lucimara Fátima Beletini; Amanda Hinobu de Souza; Priscilla de Laet Sant'Ana; Keller Karla de Lima; Carlos Cesar Crestani; Ana Lúcia Falavigna-Guilherme
Journal:  PLoS One       Date:  2021-04-15       Impact factor: 3.240

Review 8.  Treatment of toxoplasmosis: Current options and future perspectives.

Authors:  Neda Konstantinovic; Hélène Guegan; Tijana Stäjner; Sorya Belaz; Florence Robert-Gangneux
Journal:  Food Waterborne Parasitol       Date:  2019-04-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.